Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC).
Musashi-2 (MSI2)
Non-small cell lung cancer (NSCLC)
RNA binding proteins
overall survival (OS)
prediction biomarkers
Journal
Journal of thoracic disease
ISSN: 2072-1439
Titre abrégé: J Thorac Dis
Pays: China
ID NLM: 101533916
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
entrez:
12
4
2021
pubmed:
13
4
2021
medline:
13
4
2021
Statut:
ppublish
Résumé
Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
Sections du résumé
BACKGROUND
BACKGROUND
Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC).
METHODS
METHODS
The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed
RESULTS
RESULTS
MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type.
CONCLUSIONS
CONCLUSIONS
Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
Identifiants
pubmed: 33841930
doi: 10.21037/jtd-20-2787
pii: jtd-13-03-1370
pmc: PMC8024834
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1370-1379Subventions
Organisme : NCI NIH HHS
ID : P30 CA006927
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA060553
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA218802
Pays : United States
Organisme : NCI NIH HHS
ID : R21 CA223394
Pays : United States
Informations de copyright
2021 Journal of Thoracic Disease. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jtd-20-2787). The authors have no conflicts of interest to declare.
Références
Nat Rev Genet. 2016 May;17(5):257-71
pubmed: 26996076
Ann Hematol. 2013 Mar;92(3):315-23
pubmed: 23233047
Lab Invest. 2016 Sep;96(9):950-8
pubmed: 27322953
Clin Cancer Res. 2017 May 1;23(9):2143-2153
pubmed: 28143872
Proc Natl Acad Sci U S A. 2002 Nov 12;99(23):15194-9
pubmed: 12407178
Sci Rep. 2018 Jun 15;8(1):9227
pubmed: 29907753
Oncogene. 2017 Mar 23;36(12):1745-1752
pubmed: 27593929
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
Int J Oncol. 2016 Nov;49(5):1945-1952
pubmed: 27600258
Cancer Res. 2003 Mar 15;63(6):1202-6
pubmed: 12649177
Cancer Lett. 2017 Jan 1;384:50-59
pubmed: 27721018
J Clin Oncol. 2003 Oct 15;21(20):3798-807
pubmed: 12953099
PLoS One. 2013 Dec 18;8(12):e82241
pubmed: 24367507
Clin Cancer Res. 2017 Feb 1;23(3):687-696
pubmed: 27449499
Nature. 2010 Aug 5;466(7307):765-8
pubmed: 20639863
Int J Lab Hematol. 2015 Apr;37(2):272-8
pubmed: 25090928
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Proc Natl Acad Sci U S A. 2016 Jun 21;113(25):6955-60
pubmed: 27274057
Oncogene. 2010 Aug 26;29(34):4741-51
pubmed: 20531305
J Neurosci. 2001 Oct 15;21(20):8091-107
pubmed: 11588182
Nucleic Acid Ther. 2012 Aug;22(4):271-4
pubmed: 22830413
Blood. 2011 Sep 8;118(10):2857-67
pubmed: 21753187
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210